| Patent application number | Description | Published |
|---|
| 20080280318 | Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof - The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells. | 11-13-2008 |
| 20090062188 | Disease-Associated Protein - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions. | 03-05-2009 |
| 20090215679 | Disease-associated proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 08-27-2009 |
| 20090306188 | IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH - The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3′UTR sequences. The CDS sequence which codes for the protein to be delivered into the mitochondrion is guided by these appropriate MTS and 3′UTR sequences from the nuclear compartment to the mitochondrion-bound polysomes (where the CDS is translated), and aids in an efficient translocation of a mature functional protein into the mitochondria. Appropriate MTS and 3′UTR sequences correspond to those of nuclearly-transcribed mitochondrially-targeted mRNAs. The inventors demonstrate that, to obtain a stable therapeutically-effective importation, both an appropriate MTS and an appropriate 3′UTR should preferably be used. | 12-10-2009 |
| 20100184707 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation. | 07-22-2010 |
| 20100247496 | NEURONAL VIABILITY FACTOR AND USE THEREOF - The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in | 09-30-2010 |
| 20100267646 | Trophic Factor for the Treatment of Retinal Degenerative Diseases - This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides. | 10-21-2010 |
| 20110059855 | Use of adiponectin for the diagnosis and/or treatment of presbycusis - The present invention relates to mutations located within the gene coding for adiponectin, said mutations being associated with presbycusis. The present invention further relates to adiponectin polynucleotides comprising such mutations, to adiponectin polypeptides encoded by such polynucleotides, and to methods of diagnosing and/or treating presbycusis using adiponectin polynucleotides, adiponectin polypeptides and/or ADIPOR2 polypeptides. | 03-10-2011 |
| 20110105411 | Disease-Associated Proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 05-05-2011 |
